Cereno Scientific

Respiratory system
#Cereno Scientific #Clinical trial #Hypertension #Idiopathic pulmonary fibrosis

Cereno Scientific to evaluate IPF drug as PH-ILD treatment 

An innovative drug developed to treat idiopathic pulmonary fibrosis (IPF) will now be evaluated as a treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD).  CS014, a HDAC inhibitor developed by biotech company Cereno Scientific, will be studied as a treatment for PH-ILD to address a… Read More

#News

pulmonary arterial hypertension
#Cereno Scientific #Fast Track designation #FDA

Cereno Scientific granted FDA fast track designation for CS1

The US Food and Drug Administration (FDA) has granted Fast Track designation to Cereno Scientific’s lead programme, CS1, for the treatment of pulmonary arterial hypertension (PAH).  “The Fast Track designation for CS1 underscores the FDA’s recognition of its potential to address the significant unmet need in PAH,” said Rahul Agrawal,… Read More

#News #Regulatory

#Cereno Scientific #European Commission #Hypertension #Orphan drugs #Rare disease

EU orphan designation for pulmonary hypertension drug

The European Commission has granted orphan medicinal product designation (OMPD) to Cereno Scientific’s lead drug candidate CS1 for pulmonary arterial hypertension (PAH). CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed to offer improved quality of life and prolonged life for patients with PAH. Companies that obtain… Read More

#News #Regulatory